Sort
10,766 grants matching “checkpoint inhibitor”
Translational Immunology
$425,301Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Epigenetic regulation of exhausted CD8 T cells via the miR-29a-TET2 axis
$425,216Erietta Stelekati · University Of Miami School Of Medicine · R01 · FY2024 · AI
Using dietary glutamine supplementation for melanoma prevention and targeted therapy
$424,991Mei Kong · University Of California-Irvine · R01 · FY2025 · CA
Project 4 :Using TME genetics and immunobiology to drive combination immunotherapies
$424,856Elizabeth Marion Jaffee · Johns Hopkins University · P50 · FY2018 · CA
Interplay between LINE-1 retrotransposons, condensins, and IFN
$424,835Michelle S Longworth · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · GM
Analysis of the Replication Stress Response
$424,732David K Cortez · Vanderbilt University · R01 · FY2022 · GM
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer
$424,710Lauren Averett Byers · Ut Southwestern Medical Center · P50 · FY2023 · CA
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer
$424,709Lauren Averett Byers · Ut Southwestern Medical Center · P50 · FY2022 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$424,612Lei Zheng · Johns Hopkins University · R01 · FY2015 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$424,612Lei Zheng · Johns Hopkins University · R01 · FY2016 · CA
Immune activation by necroptotic cell death
$424,373Andrew Atwell Oberst · University Of Washington · R01 · FY2021 · CA
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma
$424,213Gregory B. Lesinski · Emory University · R01 · FY2020 · CA
Genetic Mechanisms Controlling Kidney Cancer Immune Escape
$424,094Haydn Kissick · Emory University · R01 · FY2024 · CA
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas
$424,015Weizhou Zhang · University Of Florida · R01 · FY2024 · CA
Project 1: Targeted sequencing and clinicopathology to evaluate primary melanoma molecular subtypes and outcomes
$423,859Marianne Berwick · University Of New Mexico Health Scis Ctr · P01 · FY2017 · CA
Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma
$423,811David McDermott · Beth Israel Deaconess Medical Center · R01 · FY2023 · CA
Cooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemia
$423,784Lili Wang · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
Targeting ER+ Breast Cancer Through Induced Viral Mimicry
$423,760Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2024 · CA
KRAS inhibitors prime cancer cells for macrophage-mediated destruction
$423,760Kipp A Weiskopf · Whitehead Institute For Biomedical Res · R01 · FY2024 · CA
Dissecting the influence of DNA damage response and homologous recombination deficiencies on tumor immunogenicity
$423,750Robert M Samstein · Icahn School Of Medicine At Mount Sinai · DP5 · FY2021 · OD
Dissecting the influence of DNA damage response and homologous recombination deficiencies on tumor immunogenicity
$423,750Robert M Samstein · Icahn School Of Medicine At Mount Sinai · DP5 · FY2023 · OD
Dissecting the influence of DNA damage response and homologous recombination deficiencies on tumor immunogenicity
$423,750Robert M Samstein · Icahn School Of Medicine At Mount Sinai · DP5 · FY2019 · OD
Dissecting the influence of DNA damage response and homologous recombination deficiencies on tumor immunogenicity
$423,750Robert M Samstein · Icahn School Of Medicine At Mount Sinai · DP5 · FY2020 · OD
Dissecting the influence of DNA damage response and homologous recombination deficiencies on tumor immunogenicity
$423,750Robert M Samstein · Icahn School Of Medicine At Mount Sinai · DP5 · FY2022 · OD
Project 2
$423,518David A Barbie · Dana-Farber Cancer Inst · P50 · FY2025 · CA